Yüklüyor......
Adverse events following immunisation with a meningococcal serogroup B vaccine: report from post-marketing surveillance, Germany, 2013 to 2016
In January 2013, a novel vaccine against Neisseria meningitidis serogroup B, the multicomponent meningococcal serogroup B vaccine (4CMenB), was approved by the European Medicines Agency. We aimed to evaluate the safety profile of this vaccine. Methods: All adverse events following immunisation (AEFI...
Kaydedildi:
| Yayımlandı: | Euro Surveill |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
European Centre for Disease Prevention and Control (ECDC)
2018
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5930728/ https://ncbi.nlm.nih.gov/pubmed/29717697 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2807/1560-7917.ES.2018.23.17.17-00468 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|